A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent

Cancer Chemotherapy and Pharmacology

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/2tPSqyc
via IFTTT